Nature Reviews Clinical Oncology http://dx.doi.org/10.1038/nrclinonc.2017.160
The Acknowledgements section in the online and PDF versions of this manuscript originally contained the text “The authors gratefully acknowledge financial support from the Prostate Cancer Clinical Trials Consortium of the Prostate Cancer Foundation, and a SPORE Center Grant to the Sidney Kimmel Center for Prostate and Urologic Cancers.” This was incorrect and has been corrected to “The authors gratefully acknowledge financial support from the Department of Defense Prostate Cancer Research Program (PC121111 and PC131984), the NIH/NCI (Cancer Center Support Grant P30-CA008748, P50-CA92629 SPORE in Prostate Cancer), the Prostate Cancer Foundation, and the Sidney Kimmel Center for Prostate and Urologic Cancers” in the online and PDF versions of this manuscript.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2017.160
Rights and permissions
About this article
Cite this article
Teo, M., O'Shaughnessy, M., McBride, S. et al. Erratum: Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nat Rev Clin Oncol 15, 150 (2018). https://doi.org/10.1038/nrclinonc.2017.177
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.177
This article is cited by
-
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Investigational New Drugs (2021)